Alpha Teknova, Inc. announced that it expects to receive $15.358495 million in funding
July 10, 2024
Share
Alpha Teknova, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 common shares at a purchase price of $1.24 per share for the gross proceeds of $15,358,494.92 on July 11, 2024. The private placement is expected to close on or about July 12, 2024, subject to the satisfaction of customary closing conditions. The offer and sale of the securities in the private placement are being made in transactions not involving a public offering and have not been registered pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and/or Rule 506(b) of Regulation D promulgated thereunder.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
ALPHA TEKNOVA, INC. 
